Inhibition of Ornithine Aminotransferase for the Treatment of Proliferative Disorders

Research output: Patent

Abstract

Inhibition of Ornithine Aminotransferase for the Treatment of Proliferative Disorders NU 2011-039 Inventors Yaron Ilan Ehud Zigmond Richard B. Silverman* Hejun Lu Abstract Cancer is one of the major causes of morbidity throughout the world. A variety of chemotherapeutic agents have been used clinically, but the presently available anti-tumor agents are known to have a variety of poor side effects, including damage to healthy cells. Furthermore, certain tumor types are resistant to treatment with these agents. Northwestern inventors have determined that ornithine aminotransferase, an enzyme involved in the conversion of ornithine to proline, is at elevated levels in malignant proliferative tissue. Furthermore, the investigators developed a pharmaceutical composition and a method of using inhibitors targeting the enzyme to decrease tumor growth. These discoveries constitute diagnostic methods and therapy for a variety of cancers, including those not treatable with more conventional chemotherapy. Applications o Diagnosis of malignant proliferating tissue o Treatment through inhibition of tumor growth Advantages o New means of diagnosis o Ability to treat rare cancers and those that don't respond to other therapies IP Status Issued US Patent No. 8,211,865 Marketing Contact Allan Nader, PhD Invention Manager (e) a-nader@northwestern.edu (p) 847.491.4456
Original languageEnglish
Patent number8211865
StatePublished - Jan 21 2010

    Fingerprint

Cite this